Tsai-Ta Lai
Vermogen: 189 M $ op 31-07-2026
Vermogen: 189 M $ op 31-07-2026
Tsai-Ta Lai held the position of Chief Technology Officer at AquaFresco, Inc., founded in 2015.
Dr. Lai is Chairman & Chief Executive Officer at Metis TechBio Co., Ltd., founded in 2020.
Dr. Lai is the founder of AquaFresco, Inc. (2015) and Metis TechBio Co., Ltd. (2020).
Dr. Lai is also the founder of METiS Therapeutics, Inc...
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 10-06-2026 | 111.166.572 ( 10,26% ) | 143 M $ | 31-07-2026 | |
METIS TECHBIO CO., LTD. 36,55% | 13-05-2026 | 36.400.278 ( 36,55% ) | 47 M $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| METIS TECHBIO CO., LTD. | Algemeen Directeur | 10-01-2020 |
METiS Therapeutics, Inc.
METiS Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for patients with diseases | Algemeen Directeur | - |
| Bedrijven | Functie | Einde |
|---|---|---|
AquaFresco, Inc.
AquaFresco, Inc. Industrial MachineryProducer Manufacturing Designs and develops water recycling technology | Oprichter | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 3 |
|---|---|
AquaFresco, Inc.
AquaFresco, Inc. Industrial MachineryProducer Manufacturing Designs and develops water recycling technology | Producer Manufacturing |
METiS Therapeutics, Inc.
METiS Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for patients with diseases | Health Technology |
Hangzhou Jitai Pharmaceutical Technology Co. Ltd.
Hangzhou Jitai Pharmaceutical Technology Co. Ltd. Chemicals: Major DiversifiedProcess Industries Operates as an investment holding company whose subsidiaries provides AI based nanomaterials delivery and application services | Process Industries |
Kies jouw editie
Alle financiële informatie op nationaal niveau